Research Progress of Nanomedicine and Its Pharmacokinetics
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics".
Deadline for manuscript submissions: closed (10 July 2023) | Viewed by 2780
Special Issue Editors
Interests: nanomedicine; physiological-based pharmacokinetics (PBPK); population pharmacokinetics (popPK)
Interests: nanomedicine; physiological-based pharmacokinetics (PBPK); population pharmacokinetics (popPK)
Interests: drug delivery; pharmaceutical nanotechnology; nanomedicine; pulmonary drug delivery; cell encapsulation; tissue engineering
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
I am pleased to invite you to contribute to a Special Issue of the peer-reviewed, open-access journal Pharmaceutics, which will be devoted to “Research progress of nanomedicine and its pharmacokinetics”. Nanomedicines are mainly designed to enhance the oral bioavailability of a drug, improve its targeting, or control its release. Consequently, it is now well known that nanomedicines modify the pharmacokinetics profile of a drug. Recently, new methods for the detection and the quantitation of nanomedicines in vitro and in vivo have been described, which allow to precisely determine the pharmacokinetics profile of the nanocarrier itself, in addition to the drug. However, it seems that classical pharmacokinetics models are not sufficient to describe the pharmacokinetics profile of nanomedicines. An accurate pharmacokinetics evaluation and modeling of nanomedicines will help them reach clinical evaluations and then the market, changing the fate of numerous diseases.
This Special Issue encourages scientists and researchers to publish their experimental results in order to capture the current state of the art in this trendy research area. All data concerning the absorption, distribution, and elimination but also physiological-based pharmacokinetics (PBPK) and population pharmacokinetics (popPK) studies of nanomedicines are encouraged.
Globally, all original research articles and reviews, including the pharmacokinetics of organic and inorganic nanomedicines, are welcome.
We look forward to receiving your contribution.
Dr. Samuel Legeay
Dr. Lebreton Vincent
Dr. Paolo Blasi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanomedicine
- physiological-based pharmacokinetics (PBPK)
- population pharmacokinetics (popPK)
